These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23165478)

  • 1. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
    Yu B; Mao Y; Bai LY; Herman SE; Wang X; Ramanunni A; Jin Y; Mo X; Cheney C; Chan KK; Jarjoura D; Marcucci G; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
    Blood; 2013 Jan; 121(1):136-47. PubMed ID: 23165478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice.
    Wacheck V; Krepler C; Strommer S; Heere-Ress E; Klem R; Pehamberger H; Eichler HG; Jansen B
    Antisense Nucleic Acid Drug Dev; 2002 Dec; 12(6):359-67. PubMed ID: 12568310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
    Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C
    J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody.
    Meissner JM; Toporkiewicz M; Czogalla A; Matusewicz L; Kuliczkowski K; Sikorski AF
    J Control Release; 2015 Dec; 220(Pt A):515-528. PubMed ID: 26585505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts.
    Smith MR; Jin F; Joshi I
    Mol Cancer Ther; 2004 Dec; 3(12):1693-9. PubMed ID: 15634664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential therapeutic applications of oblimersen in CLL.
    Koziner B
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):32-8. PubMed ID: 15651175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro modulation of bcl-2 protein expression, drug-induced apoptosis and cytotoxicity by interleukin-10 in chronic lymphocytic leukemia.
    Morabito F; Filangeri M; Sculli G; Oliva B
    Haematologica; 1998 Nov; 83(11):1046-8. PubMed ID: 9864930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
    Marcucci G; Byrd JC; Dai G; Klisovic MI; Kourlas PJ; Young DC; Cataland SR; Fisher DB; Lucas D; Chan KK; Porcu P; Lin ZP; Farag SF; Frankel SR; Zwiebel JA; Kraut EH; Balcerzak SP; Bloomfield CD; Grever MR; Caligiuri MA
    Blood; 2003 Jan; 101(2):425-32. PubMed ID: 12393493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model.
    Zhang X; Koh CG; Yu B; Liu S; Piao L; Marcucci G; Lee RJ; Lee LJ
    Pharm Res; 2009 Jun; 26(6):1516-24. PubMed ID: 19291371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy.
    Gjertsen BT; Bredholt T; Anensen N; Vintermyr OK
    Curr Pharm Biotechnol; 2007 Dec; 8(6):373-81. PubMed ID: 18289046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM
    Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
    Ramanarayanan J; Hernandez-Ilizaliturri FJ; Chanan-Khan A; Czuczman MS
    Br J Haematol; 2004 Dec; 127(5):519-30. PubMed ID: 15566355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.
    Tolcher AW
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):635-42, 662. PubMed ID: 16167050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.
    Lopes de Menezes DE; Hu Y; Mayer LD
    J Exp Ther Oncol; 2003; 3(2):72-82. PubMed ID: 12822513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
    Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
    J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.